Orchard’s management team has extensive expertise in R&D, manufacturing and commercialization of rare diseases and gene therapy.
Mark brings 28 years of experience in the bio-pharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialisation. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs.
Prior to Orchard Therapeutics, Mark served as Chief Commercial Officer of PTC Therapeutics (“PTC”) where he helped transition the company from a privately funded, US-based R&D biotech to a public, commercial stage company with a 47 country commercialisation footprint. This he achieved by building a global commercialisation capability and successfully launching two rare disease therapies.
Prior to joining PTC, Mark served as Global President of Aegerion Pharmaceuticals Inc. and Head EMEA region at Shire Human Genetics. Mark received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.close profile
John brings over 25 years of HR leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission driven and entrepreneurial companies.
Until recently John served as Vice President of Human Resources and Administration for Agenus where he led the HR function through periods of rapid growth, transformation and global expansion including the acquisition and integration of 4-antibody AG and the recruiting and on-boarding of over 150 R&D staff, responsible for creating and advancing an Immuno-oncology portfolio of over a dozen clinical candidates including 4 that are currently in phase 2. Prior to Agenus, he was Vice President of Global HR for PerkinElmer Life Sciences during which time the company more than doubled in size and annual sales. Earlier in his career, John spent nearly 10 years with Bristol-Myers Squibb company in a series of HR leadership roles with increasing responsibilities ranging from Director of HR for Corporate Staff to Head of HR for their Oncology and Immunology division.
John earned his B.S. in Industrial and Labor Relations from Cornell and his M.A. in Organizational Psychology from Columbia. He also completed the Global Leadership Development Programme at the London Business School.
Moya brings to Orchard Therapeutics more than 25 years of experience in cGMP manufacturing, quality systems, and clinical and regulatory affairs for the global development of tissue, cell and gene-based therapies.
Prior to joining Orchard Therapeutics, she was Vice President, Regulatory Affairs and Quality Assurance at Fate Therapeutics (FATE). As a member of the Executive Leadership Team, she was responsible for building a quality management system, developing regulatory strategy and leading interactions with the Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Pharmaceuticals and Medical Devices Agency (PMDA).
Moya has a successful track record of building and leading quality and regulatory teams in the setting of both early and late stages of development. Over the past 18 years, she has worked on the development of tissue and cell-based therapies for orphan drug products for the treatment of rare diseases.
One of Moya’s significant career achievements was leading the business unit which was responsible for obtaining approval for the first allogeneic stem cell therapy for graft versus host disease in Canada and New Zealand. She holds a Bachelor of Science degree in biology from Saint Augustine’s College, completed a master’s level of education in basic medical science at Ross University School of Medicine and has a master’s degree in Healthcare Administration from the University of Maryland.close profile
Anne brings to Orchard Therapeutics more than 20 years of experience of tackling R&D, clinical and regulatory challenges for global development within medtech and biotech companies.
Prior to joining Orchard Therapeutics, she was Executive Vice President at VCLS (Voisin Consulting Life Sciences), where she was actively involved in the design, preparation and management of high number of successful regulatory submissions at all stages of product development. She managed over 50 different cell, tissue and gene based therapies development programs over the last 3 years. She established strong communication links with Regulators, including the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA).
Anne possesses extensive expertise in human Cell, Tissue and Gene Therapies, so called Advanced Therapy Medicinal Products (ATmPs) in Europe. Bringing together scientific and regulatory expertise in this area, she actively participated in the elaboration of the European ATmPs’ Regulation through Industry Associations and worked closely with the European Medicines Agency (EMA) on related guidelines.
Anne began her career as a Research & Development Project Manager for Medtronic Sofamor-Danek after earning a joint PhD degree from the University of Dental Surgery in Nantes, France, the Free University of Berlin, Germany and the University of Medicine of Leiden, Netherlands, working on the development and evaluation of drug-device combination products aimed at bone substitution. Before joining VCLS, Anne co-founded the regulatory consulting firm Meditest International.close profile
Bobby is Professor of paediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in paediatric immunology at Great Ormond Street Hospital, London.
He has a special interest in the treatment of severe primary immune deficiencies, including bone marrow transplantation, gene and cell therapy. He has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies.
Bobby is currently leading UK and European-wide initiatives for newborn screening in severe combined immune deficiency. He is Director of the Centre for Research in Rare Diseases in Children (CRRDC), a new academic and clinical facility that will open at Great Ormond Street in 2018.close profile
John brings broad expertise in corporate, commercial and IP law. He has extensive experience in legal, compliance and corporate secretarial roles in international biopharmaceutical and life sciences companies. He also brings commercial and biotech intellectual property experience.
Prior to joining Orchard, John was a non-executive director at Oxular Limited and group general counsel & company secretary at Consort Medical plc. He held senior legal affairs roles at several companies operating in the rare disease space including Synageva, BioMarin and Oxford GlycoSciences.
John is a qualified solicitor. He received his Bachelor of Law degree in Business Law from City of London, his postgraduate diploma in EC Competition Law from King's College, London and a postgraduate diploma in Intellectual Property Law from Queen Mary University of London.close profile
Adrien brings to Orchard Therapeutics more than 15 years of experience growing pharma and biotech businesses via in- and out-licensing, M&A and portfolio development.
Prior to joining Orchard, Adrien was Executive Director, Corporate Strategy and Development at AstraZeneca where he was leading M&A activities as well as successful out-licensing and new companies spin-off projects. He was a member of the Board of Directors of Corvidia Therapeutics.
Prior to AstraZeneca, Adrien spent 9 years at GSK and his most recent experience was Strategy & Operations Director in the Rare Diseases Unit, where he worked in particular on the in-licensing of the TIGET (the Telethon Institute of Gene Therapy) autologous gene therapy portfolio and other successful business development activities. He was a member of the Advisory Committee for Kurma BioFund II, a venture capital fund with a special focus on rare diseases.
His experience at GSK also encompasses European and global roles of increasing seniority in R&D portfolio strategy and commercial analysis. He started his career as a strategy consultant at Alcimed (Paris, France), supporting the development of biotechnology start-up companies. Adrien holds an Engineering Degree from Supélec (Paris, France) and a MSc in Engineering and Physical Science in Medicine from Imperial College (London, UK).close profile
Jason brings extensive global commercialization experience to Orchard including the launch of multiple therapies for ultra-rare life-threatening diseases, new market entry strategies, market access and organizational development. He led the global commercialization of gene therapies for primary immune deficiencies and inherited metabolic disorders.
Prior to joining Orchard, Jason served as chief commercial officer at Sucampo Pharmaceuticals, Inc. and Vtesse. He also led commercial operations at Alexion in the U.S. and Latin America in the haematology, nephrology and metabolic business units, and held commercial leadership roles expanding access to the company's products in Europe, the Middle-East, Africa and Japan.
Jason holds a Bachelor of Science in Biochemistry from the University of Maryland and a Master of Business Administration from Duke University's Fuqua School of Business.close profile
Katie Payne brings nearly 20 years of communications, stakeholder engagement and health policy expertise to Orchard Therapeutics as senior vice president of corporate communications and external affairs.
Her responsibilities at Orchard include directing the company’s internal and external communications, patient advocacy, investor relations and government relations functions. Katie joined Orchard from AMAG Pharmaceuticals, where she served as senior vice president of corporate affairs, overseeing all communications, government relations and advocacy activities. During her time at AMAG, Katie led the internal and external communications strategy for six significant corporate and business development transactions and played a key role in the company’s efforts to collaborate with healthcare experts and advocacy groups to advance public health. Her expertise includes stakeholder engagement, issues and crisis management, media relations and corporate identity. Prior to AMAG, Katie spent a decade at a global communications and public affairs firm where she developed and implemented U.S. and global communications programs for a wide variety of companies and organizations in the healthcare industry. She also served as a communications associate at The World Bank in Washington, D.C., and as a healthcare research associate for Forrester Research.
Katie graduated Phi Beta Kappa and with high honors from The Johns Hopkins University with a Bachelor of Arts degree in writing and business management and a master’s degree in communications. She currently serves as a member of the MassBio Board of Directors and is also a member of the Board of Directors of the Boston-Manchester March of Dimes chapter.close profile
Andrea is a co-founder of Orchard Therapeutics and brings to the company extensive experience and expertise in the development and execution of all aspects of clinical development and particularly in paediatric rare diseases.
Prior to joining Orchard Therapeutics, Andrea served as VP and Medicine Development Leader at GSK Rare Diseases Unit. Previous to joining the GSK Rare Diseases Unit, Andrea was Senior Medical Director at the Immune Inflammation Discovery Performance Unit. Before GSK, Andrea was Global Medical Director R&D at Takeda in the metabolic and cardiovascular area and in charge of the paediatric developments for Takeda Europe R&D. Before that, she worked as Research Physician at Hammersmith Medicines Research. Before moving to the pharmaceutical industry Andrea practiced as a paediatrician for 12 years in Argentina, Spain and UK.
Andrea was recognized as one of 2018’s ”Fiercest Women in Life Sciences” by FiercePharma and also as one of BioBeat’s “50 Movers & Shakers in BioBusiness 2017.” She obtained her medical degree from the University of Buenos Aires (UBA) and completed residency in paediatrics and post graduate training in paediatric immunology at the Dr Elizalde Children's Hospital in Buenos Aires, Argentina. Andrea also obtained a Specialist in Pharmaceutical Medicine degree from University of Basel, Switzerland, and she is a Fellow of the Faculty of Pharmaceutical Medicine in London, UK (FFPM).close profile
Frank brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive. Frank has a background developing and executing capital markets strategies for private and public companies as well as experience in operations management, and corporate and business development.
Until recently Frank served as president and chief operating officer of AMAG Pharmaceuticals where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support the significant growth of AMAG.
Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief financial officer for Critical Therapeutics and Esperion Therapeutics. Each completed its initial public offering in the United States during his tenure. Frank currently serves on the board of directors of Zafgen (Nasdaq: ZFGN) and Spero Therapeutics (Nasdaq: SPRO). Frank received a Bachelor of Business Administration (BBA) from the University of Michigan, Ann Arbor.close profile
Ran Zheng brings more than 20 years of experience in technical operations, and oversees multiple related functions for Orchard Therapeutics, including process development, manufacturing, quality, facilities and engineering, supply chain, and CMC program management.
Prior to Orchard, Ran spent 16 years with Amgen in roles of increasing responsibility in operations. Most recently, she served as vice president of development supply chain, overseeing end-to-end supply chain, development labs and pilot plants and manufacturing operations across multiple geographic locations to enable Amgen's global clinical development, product launch, commercial supply and technology innovation. Before her tenure with Amgen, Ran held various leadership positions in process development and process engineering at Diosynth and Genzyme.
Ran holds a Bachelor of Science degree from Beijing Forestry University and Master of Science degree in Microbial Engineering and Chemical Engineering from the University of Minnesota.close profile